Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Psychiatry. 2006 Jan;163(1):153-5.

A double-blind, placebo-controlled study of memantine in the treatment of major depression.

Author information

1
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA. zaratec@mail.nih.gov

Abstract

OBJECTIVE:

This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans.

METHOD:

In a double-blind, placebo-controlled study, 32 subjects with major depression were randomly assigned to receive memantine (5-20 mg/day) (N=16) or placebo (N=16) for 8 weeks. Primary efficacy was assessed by performance on the Montgomery-Asberg Depression Rating Scale (MADRS).

RESULTS:

The linear mixed models for total MADRS scores showed no treatment effect.

CONCLUSIONS:

In an 8-week trial, the low-to-moderate-affinity NMDA antagonist memantine in doses of 5-20 mg/day was not effective in the treatment of major depressive disorder.

PMID:
16390905
DOI:
10.1176/appi.ajp.163.1.153
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center